Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

Monthly doses of palivizumab, an RSV-specific monoclonal antibody, reduce RSV-related hospitalizations (RSVH) in high-risk children; however, no specific palivizumab level has been correlated with disease severity in humans. A post hoc analysis of a previous randomized, placebo-controlled trial eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Forbes, Michael L, Kumar, Veena R, Yogev, Ram, Wu, Xionghua, Robbie, Gabriel J, Ambrose, Christopher S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443068/
https://www.ncbi.nlm.nih.gov/pubmed/25483663
http://dx.doi.org/10.4161/hv.29635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443068/
https://www.ncbi.nlm.nih.gov/pubmed/25483663
http://dx.doi.org/10.4161/hv.29635

Ejemplares similares